Capturing O
spontaneous O
activity O
in O
the O
medial O
prefrontal O
cortex O
using O
near-infrared O
spectroscopy O
and O
its O
application O
to O
schizophrenia O
Near-infrared O
spectroscopy O
( O
NIRS O
) O
is O
an O
optimal O
imaging O
modality O
used O
to O
examine O
spontaneous O
brain O
activity O
because O
it O
can O
quietly O
measure O
blood O
flow O
changes O
with O
less O
physical O
restriction O
during O
the O
resting O
state O
. O

Here O
, O
NIRS O
was O
used O
at O
rest O
to O
measure O
spontaneous O
activity O
in O
the O
medial O
prefrontal O
cortex O
( O
mPFC O
) O
, O
a O
main O
locus O
of O
default O
mode O
network O
. O

Consistent O
with O
previous O
fMRI O
studies O
, O
magnitude O
of O
the O
spontaneous O
activity O
in O
this O
region O
declined O
with O
increasing O
age O
in O
healthy O
subjects O
. O

The O
magnitude O
reduced O
in O
the O
mPFC O
of O
patients O
with O
schizophrenia O
. O

Additionally O
, O
in O
the O
mPFC O
of O
patients O
with O
schizophrenia O
, O
the O
spontaneous O
activity O
did O
not O
show O
any O
age-related O
decline O
; O
the O
activity O
was O
already O
low O
in O
younger O
patients O
. O

Further O
analysis O
using O
fractional O
amplitude O
of O
low-frequency O
fluctuations O
confirmed O
the O
reduction O
of O
spontaneous O
activity O
in O
the O
mPFC O
of O
patients O
with O
schizophrenia O
, O
consistent O
with O
the O
findings O
of O
fMRI O
studies O
. O

Our O
findings O
demonstrate O
the O
ability O
of O
NIRS O
to O
evaluate O
the O
spontaneous O
activity O
in O
the O
mPFC O
of O
patients O
with O
schizophrenia O
, O
particularly O
younger O
patients O
. O

Considering O
the O
safety O
and O
ease O
of O
the O
NIRS O
measurements O
, O
the O
current O
NIRS O
study O
of O
the O
resting-state O
activity O
indicates O
its O
utility O
for O
clinical O
applications O
to O
schizophrenia O
, O
which O
may O
facilitate O
chronological O
assessment O
of O
larger O
cohorts O
of O
patients O
with O
schizophrenia O
in O
further O
studies O
. O

Methods O
Subjects O
Fifty-three O
healthy O
, O
right-handed O
males O
aged O
between O
23 O
and O
66 O
years O
( O
mean O
± O
s.e.m O
. O

= O
41.1 O
± O
1.5 O
) O
with O
no O
history O
of O
neurological O
or O
psychiatric O
disorders O
participated O
in O
this O
study O
. O

Twenty O
right-handed O
male O
patients O
( O
25–68 O
years O
, O
50.6 O
± O
3.0 O
) O
hospitalised O
with O
schizophrenia O
and O
having O
apparent O
deficits O
in O
social O
functioning O
based O
on O
a O
GAF O
score O
of O
≤35 O
were O
also O
included O
. O

Two O
or O
more O
psychiatrists O
diagnosed O
each O
patient O
on O
the O
basis O
of O
the O
DSM-5 O
criteria O
for O
schizophrenia O
. O

The O
diagnosis O
was O
verified O
based O
on O
detailed O
clinical O
observations O
during O
hospitalisation O
. O

All O
patients O
were O
administered O
antipsychotics O
, O
and O
none O
had O
a O
history O
of O
substance/alcohol O
abuse O
. O

Clinical O
variables O
of O
the O
patients O
were O
as O
follows O
: O
GAF O
score O
, O
24.2 O
± O
1.4 O
; O
illness O
duration O
, O
27.9 O
± O
3.5 O
years O
; O
onset O
age O
, O
23.9 O
± O
1.6 O
years O
; O
and O
chlorpromazine-equivalent O
antipsychotic O
dose O
, O
804.5 O
± O
143.7 O
mg/day O
. O

The O
symptoms O
of O
the O
patients O
with O
schizophrenia O
were O
assessed O
based O
on O
Clinician-Rated O
Dimensions O
of O
Psychosis O
Symptom O
Severity O
( O
CRDPSS O
) O
by O
two O
research O
psychiatrists O
who O
were O
blinded O
to O
the O
NIRS O
data O
, O
along O
with O
the O
information O
obtained O
from O
the O
clinical O
psychiatrist O
in O
charge O
and O
ward O
nurses O
. O

The O
CRDPSS O
scores O
were O
as O
follows O
; O
Hallucinations O
( O
mean O
± O
s.e.m O
. O

= O
2.5 O
± O
0.3 O
, O
Delusions O
( O
2.6 O
± O
0.2 O
) O
, O
Disorganized O
speech O
( O
3.0 O
± O
0.2 O
) O
, O
Abnormal O
psychomotor O
behaviour O
( O
2.5 O
± O
0.2 O
) O
, O
Negative O
symptoms O
( O
3.3 O
± O
0.2 O
) O
, O
Impaired O
cognition O
( O
3.2 O
± O
0.2 O
) O
, O
Depression O
( O
0.9 O
± O
0.1 O
) O
and O
Mania O
( O
0.3 O
± O
0.2 O
) O
. O

A O
complete O
description O
of O
the O
study O
was O
provided O
, O
and O
written O
informed O
consent O
was O
obtained O
from O
all O
subjects O
. O

The O
study O
was O
approved O
by O
the O
Ethics O
Committee O
of O
the O
Kindai O
University O
Faculty O
of O
Medicine O
and O
was O
conducted O
in O
accordance O
with O
the O
relevant O
guidelines O
and O
regulations O
. O

Near-infrared O
spectroscopy O
NIRS O
measurements O
were O
conducted O
using O
a O
10-channel O
NIRS O
device O
( O
WOT-100 O
system O
; O
Hitachi O
High-Technologies O
Corporation O
, O
Tokyo O
, O
Japan O
) O
, O
as O
previously O
described O
. O

Briefly O
, O
the O
device O
measured O
relative O
changes O
in O
oxygenated- O
( O
oxy- O
) O
and O
deoxygenated- O
( O
deoxy- O
) O
haemoglobin O
( O
Hb O
) O
concentrations O
using O
two O
wavelengths O
( O
705 O
and O
830 O
nm O
) O
with O
a O
sampling O
rate O
of O
200 O
ms. O
Optical O
data O
were O
analysed O
using O
the O
modified O
Beer–Lambert O
law O
to O
calculate O
the O
signals O
reflecting O
changes O
in O
Hb O
levels O
expressed O
as O
arbitrary O
units O
( O
mM–mm O
) O
because O
the O
differential O
path O
lengths O
of O
the O
wavelengths O
are O
indefinite O
in O
this O
system O
. O

The O
NIRS O
probe O
unit O
has O
a O
2 O
× O
4 O
alternating O
arrangement O
of O
irradiation O
and O
detection O
positions O
. O

The O
lowest O
probes O
were O
positioned O
along O
the O
Fp1-Fp2 O
line O
, O
according O
to O
the O
International O
10–20 O
system O
. O

The O
distance O
between O
pairs O
of O
emission O
and O
detector O
probes O
was O
set O
at O
30 O
mm O
, O
and O
the O
measurement O
area O
between O
the O
probes O
was O
defined O
as O
a O
channel O
. O

The O
arrangement O
of O
channels O
covered O
the O
entire O
forehead O
to O
monitor O
activation O
in O
prefrontal O
regions O
. O

This O
experimental O
setup O
was O
corroborated O
by O
that O
of O
a O
multi-individual O
study O
of O
anatomical O
craniocerebral O
correction O
using O
the O
International O
10–20 O
system O
. O

Three-dimensional O
coordinates O
of O
the O
channels O
were O
obtained O
from O
six O
healthy O
subjects O
using O
a O
three-dimensional O
digitiser O
( O
Patriot O
, O
POLHEMUS O
, O
Inc. O
, O
Colchester O
, O
Vermont O
, O
USA O
) O
, O
and O
the O
mean O
estimate O
for O
the O
spatial O
registration O
of O
the O
channels O
using O
the O
probabilistic-determination O
method O
was O
mapped O
onto O
the O
Montreal O
Neurological O
Institute O
space O
based O
on O
NIRS-SPM O
( O
http O
: O
//bispl.weebly.com/nirs-spm.html O
# O
/ O
) O
, O
as O
shown O
in O
Fig O
. O

3a O
and O
Supplementary O
Table O
S1 O
. O

Resting-state O
paradigm O
For O
the O
resting-state O
acquisition O
, O
the O
subjects O
were O
seated O
in O
a O
comfortable O
chair O
in O
a O
silent O
room O
. O

They O
were O
instructed O
to O
keep O
their O
eyes O
open O
and O
remain O
still O
while O
focusing O
on O
the O
central O
fixation O
point O
( O
cross O
hair O
) O
displayed O
on O
a O
monitor O
. O

The O
NIRS O
measurement O
commenced O
when O
the O
cross O
hair O
appeared O
on O
the O
monitor O
and O
continued O
for O
three O
minutes O
at O
rest O
. O

Data O
analysis O
Magnitude O
of O
low-frequency O
fluctuations O
( O
Δoxy-Hbpeak O
) O
Relative O
changes O
in O
oxy-Hb O
signals O
were O
analysed O
according O
to O
a O
previous O
report O
that O
demonstrated O
a O
strong O
correlation O
between O
oxy-Hb O
NIRS O
measurements O
and O
blood O
oxygenation O
level-dependent O
signals O
measured O
using O
fMRI O
. O

Further O
, O
relative O
changes O
in O
deoxy-Hb O
signals O
were O
analysed O
supplementarily O
. O

The O
time O
courses O
of O
oxy- O
and O
deoxy-Hb O
signals O
were O
diagrammed O
using O
the O
BRainSuite_Analyzer O
( O
BRSystems O
. O

Inc. O
, O
Kanagawa O
, O
Japan O
) O
with O
low O
pass O
filter O
( O
< O
0.1 O
Hz O
) O
to O
eliminate O
physiological O
noises O
, O
such O
as O
those O
of O
heart O
beat O
, O
respiration O
and O
quick O
body O
movements O
. O

Figure O
3b O
presents O
the O
representative O
time O
course O
of O
oxy- O
and O
deoxy-Hb O
signals O
during O
the O
resting O
state O
. O

To O
represent O
the O
magnitude O
of O
low-frequency O
fluctuations O
during O
the O
resting O
state O
, O
Δoxy-Hbpeak O
was O
indexed O
as O
the O
peak O
value O
minus O
the O
lowest O
value O
for O
oxy-Hb O
signals O
during O
the O
resting O
state O
( O
Fig O
. O

3b O
) O
. O

The O
Δoxy-Hbpeak O
was O
calculated O
for O
the O
10 O
individual O
channels O
of O
NIRS O
, O
and O
selectively O
, O
the O
following O
region O
of O
interest O
( O
ROI O
) O
was O
chosen O
to O
examine O
the O
spontaneous O
activity O
. O

The O
ROI O
was O
set O
as O
channels O
5 O
and O
6 O
located O
on O
the O
superficial O
part O
of O
the O
mPFC O
, O
and O
then O
, O
the O
Δoxy-Hbpeak O
of O
channels O
5 O
and O
6 O
were O
averaged O
for O
the O
ROI O
signal O
. O

Fractional O
Amplitude O
of O
the O
low O
frequency O
fluctuations O
( O
fALFF O
) O
fALFF O
was O
calculated O
using O
the O
ALFF/fALFF O
software O
( O
BRSystems O
Inc. O
; O
Brainsuit O
ALFF O
; O
Kanagawa O
, O
Japan O
) O
according O
to O
previous O
reports O
. O

In O
this O
software O
, O
first O
, O
the O
time O
series O
for O
each O
channel O
was O
transformed O
to O
a O
frequency O
domain O
using O
the O
fast O
Fourier O
transform O
, O
and O
the O
power O
spectrum O
was O
obtained O
. O

Then O
, O
the O
square O
root O
was O
calculated O
at O
each O
frequency O
of O
the O
power O
spectrum O
. O

The O
sum O
of O
the O
square O
root O
across O
the O
low-frequency O
range O
( O
0.01–0.08 O
Hz O
) O
was O
divided O
by O
that O
across O
the O
entire O
frequency O
range O
( O
0–0.25 O
Hz O
) O
to O
calculate O
fALFF O
. O

The O
fALFF O
was O
analysed O
for O
ROI O
as O
selected O
in O
the O
previous O
section O
. O

Statistical O
analysis O
Between-group O
difference O
of O
the O
NIIRS O
data O
between O
the O
patients O
with O
schizophrenia O
and O
healthy O
subjects O
was O
examined O
using O
a O
general O
linear O
model O
with O
the O
Δoxy−/deoxy-Hbpeak O
or O
fALFF O
as O
dependent O
variables O
, O
group O
( O
patients O
with O
schizophrenia/healthy O
subjects O
) O
as O
a O
between-subject O
factor O
and O
age O
as O
a O
covariate O
. O

To O
examine O
the O
relationships O
between O
the O
Δoxy−/deoxy-Hbpeak O
or O
fALFF O
and O
clinical O
variables O
in O
patients O
with O
schizophrenia O
, O
Spearman O
’ O
s O
correlation O
coefficient O
( O
rs O
) O
was O
initially O
analysed O
. O

If O
any O
significance O
was O
found O
, O
multiple O
regression O
analysis O
was O
conducted O
with O
the O
NIRS O
measurements O
as O
dependent O
variables O
, O
thereby O
controlling O
for O
other O
potential O
confounding O
variables O
( O
age O
and O
antipsychotic O
dose O
) O
, O
and O
added O
factors O
such O
as O
GAF O
and O
CRDPSS O
scores O
. O

The O
threshold O
for O
the O
significance O
of O
p-values O
was O
set O
at O
0.05 O
. O

All O
statistical O
tests O
were O
two-tailed O
and O
were O
performed O
using O
GraphPad O
Prism O
6.0 O
for O
Windows O
version O
6.07 O
( O
GraphPad O
Software O
, O
Inc. O
, O
La O
Jolla O
, O
CA O
, O
USA O
) O
or O
SPSS O
version O
25.0 O
( O
IBM O
Inc. O
, O
New O
York O
, O
USA O
) O
. O

Exclusion O
of O
probe O
error O
channels O
Within O
the O
10 O
channels O
measured O
using O
NIRS O
, O
those O
judged O
to O
be O
probe O
errors O
for O
each O
subject O
by O
the O
WOT-100 O
software O
were O
excluded O
from O
the O
analysis O
. O

According O
to O
this O
criterion O
, O
ch O
. O

1 O
and O
ch O
. O

9 O
were O
excluded O
for O
one O
healthy O
subject O
and O
ch O
. O

10 O
was O
excluded O
for O
two O
. O

In O
schizophrenia O
, O
ch O
. O

2 O
and O
ch O
. O

3 O
were O
excluded O
for O
two O
patients O
, O
ch O
. O

7 O
and O
ch O
. O

9 O
were O
excluded O
for O
one O
, O
ch O
. O

8 O
was O
excluded O
for O
three O
, O
and O
ch O
. O

10 O
was O
excluded O
for O
seven O
. O

Notably O
, O
ch O
. O

4 O
, O
ch O
. O

5 O
and O
ch O
. O

6 O
were O
intact O
for O
all O
healthy O
subjects O
and O
patients O
with O
schizophrenia O
. O

